Appendix 4E and FY26 Annual Report
Filed with ASX · · 93 pages · English
Summary by 6ix AI
The report highlights a decrease in operational losses compared to the previous year, attributed to reduced research and development expenditures. The company also reported positive preclinical data and successful regulatory inspections, reinforcing its position in the fight against antimicrobial resistance.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Recce Pharmaceuticals Ltd. on 6ix
In the deck
Earlier from Recce Pharmaceuticals
- HREC Approves Comparator Study for Pivotal Phase 3 DFI
- Vietnamese Patent Granted for RECCE Anti-Infectives
- AUD $3.7M Income Tax Refund Received
- Placement & SPP to raise $8 million
- HREC Approval Accelerates Global Phase 3 DFI Strategy
Later from Recce Pharmaceuticals
- Amendments to Debt Facility with Avenue Capital Group
- Independent Review of Indonesian Phase 3 R327G Trial Data
- License and Commercialisation Agreement in AUS/NZ for R327G
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals